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We report a case of a 51-year-old woman with Evans syndrome (autoimmune hemolytic 
anemia and primary immune thrombocytopenia) and hypothyroidism. She was pre-
viously diagnosed with Hashimoto’s thyroiditis in 1994 (age, 35) and autoimmune hemo-
lytic anemia (AIHA) 3 years ago. She was treated with oral prednisolone. After a period, 
in which the anemia waxed and waned, there was an abrupt development of thrombocyto-
penia (nadir 15×10
9/L) that coincided with the tapering off of prednisolone after 3 years 
of administration. Because her thrombocytopenia was refractory to prednisolone, we ad-
ministered rituximab (375 mg/m
2 weekly) for 4 weeks. Two weeks after the completion 
of the rituximab treatment, her platelet count was up to 92×10
9/L. No intermittent peaking 
of thyroid stimulating hormone occurred after rituximab treatment was initiated. Evans 
syndrome and autoimmune thyroiditis might share common pathophysiological 
mechanisms. This notion supports the use of rituximab in a patient suffering from these 
disorders.
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INTRODUCTION
The association between primary immune thrombocyto-
penia (ITP) and autoimmune hemolytic anemia (AIHA) was 
first reported by Evans et al. in 1951. This clinical entity 
is generally referred to as Evans syndrome. Most scholars 
accept that ITP and AIHA share some pathophysiological 
mechanisms. Since this first report, there have been many 
reports of Evans syndrome in association with other auto-
immune diseases. Hashimoto’s disease is one of the most 
common autoimmune diseases and is often associated with 
other non-endocrine autoimmune diseases. Evans syndrome 
is a non-endocrine autoimmune disease and can present with 
anti-thyroid auto-antibodies [1]. Although it is assumed that 
autoimmune thyroiditis and Evans syndrome have over-
lapping immunological mechanisms, to date, there has been 
little evidence to support this assumption. Here, we present 
a 50-year-old female patient who was diagnosed with 
Hashimoto’s disease, AIHA, and ITP over a 16-year period.
The patient was diagnosed with Hashimoto’s disease and 
overt hypothyroidism in May 1994 and AIHA in October 
2006. We prescribed synthetic thyroxine and prednisolone 
for Hashimoto’s disease and AIHA, respectively. The pre-
dnisolone dose was tapered to 2.5 mg every other day. 
Subsequently, after 22 months, in September 2009, she devel-
oped ITP and was diagnosed with Evans syndrome (the com-
bination of AIHA and ITP).
Treatment options for Evans syndrome include cortico-
steroids; intravenous immunoglobulin; immunosuppressive 
drugs such as danazol and rituximab; splenectomy; and stem 
cell transplantation [2]. Recently, the use of rituximab has 
shown promising results [2, 3]. Several cases of combined 
Evans syndrome and thyroid endocrine dysfunction 
(hyperthyroidism or hypothyroidism) have been reported 
[1, 4, 5]. However, to the best of our knowledge, this is 
the first Korean report that describes a case with the sequen-
tial development of autoimmune thyroiditis, AIHA, and ITP, 
and was successfully treated with rituximab.
CASE REPORT
A 51-year-old female patient visited the outpatient clinic 
of the Department of Hematology for regular follow-up visit 
for her AIHA in September 2009. She was diagnosed with 
Hashimoto’s thyroiditis and had been taking synthetic thy-
roid hormone for hypothyroidism since 1994. In 2001, her Korean J Hematol 2011;46:279-82.
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Fig. 1. Trends in Hb level and platelet count with PD dosage and rituximab treatment. PD indicates dose of prednisolone. The units of Hb and PLT
in this figure are g/dL and ×10
4/μL, respectively. Date of diagnosis of diseases and treatment of rituximab is expressed at the bottom of figure. 
Increase in dose of PD elevated Hb level but not PLT level. PLT level is increased after the use of rituximab.
anti-microsomal antibody level increased to 1:6,400, but we 
did not have data about her thyroid autoantibody level at 
diagnosis. In September 2006, she was admitted to the hospi-
tal due to dizziness and jaundice, and was subsequently diag-
nosed with AIHA. Serologic testing showed elevations in 
anti-microsomal antibody (49 U/mL) and thyroglobulin 
antibody. Thyroid stimulating hormone (TSH) receptor anti-
body level was normal (0.3%). The results of a serologic 
test for anti-nuclear antibody were positive. Both direct and 
indirect Coombs tests also gave positive results. The tests 
for human immunodeficiency virus (HIV) antibody, hepatitis 
B surface (HBs) antigen, HBs antibody, hepatitis C virus 
(HCV) antibody, and IgM hepatitis A virus (HAV) antibody 
were all negative.
After this diagnosis, her hemoglobin level waxed and 
waned between 6 g/dL and 11 g/dL based on the dose of 
prednisolone being taken at the time. During this time, she 
refused to undergo a splenectomy.
Abrupt thrombocytopenia (68×10
9/L) was detected during 
a regular follow-up on September 1, 2009. During that visit, 
she also co mplained o f weigh t gain o f 10 kg th at  h ad o ccurred 
during the past 3 years. On physical examination, she showed 
no signs of exophthalmos. The abdomen was soft and flat, 
and the liver and spleen were not palpable. Her platelet 
count was 179×10
9/L during her previous visit in July 2009. 
The patient had persistent thrombocytopenia (21×10
9/L to 
30×10
9/L) for the subsequent 3 months while she was taking 
prednisolone (2.5 mg/day). On the other hand, her hemoglo-
bin level remained stable (10 g/dL to 13 g/dL) during the 
3-month period. No abnormal findings were observed on 
bone marrow biopsy, and bone marrow cellularity was nor-
mal (40%). Normal levels of erythropoiesis and granulopoi-
esis were observed, and the number of megakaryocytes was 
slightly high. There were no cytogenetic abnormalities. On 
the basis of these results of bone marrow biopsy, she was 
diagnosed as having ITP. Serologic testing showed elevations 
in anti-thyroglobulin antibody (＞2,000 U/mL) and anti-mi-
crosomal antibody (80.3 U/mL), and the serum was positive 
for the anti-nuclear antibody test (1:640×, cytoplasmic pat-
tern).
After the diagnosis of ITP, the dose of prednisolone was 
increased to 1 mg/kg (60 mg). While prednisolone was being 
tapered back down over a period of 4 months, the platelet 
count decreased to 7×10
9/L. Rituximab (375 mg/m
2) was ad-
ministered once a week for 4 weeks along with 1 mg/kg 
prednisolone from May 20, 2010 till June 10, 2010. Rituximab 
was well tolerated, and the platelet count rapidly increased 
to 92×10
9/L by 2 weeks after the completion of the fourth 
dose of rituximab. Azathioprine and danazol were also added 
to the treatment regimen. Azathioprine 100 mg was added 
from June 17 till September 16 (for 3 months) and danazol 
300 mg was added from June 29 to August 31. Considering 
median time to response (usually few months) of these drugs, 
elevation of platelet count was due to rituximab. Hence, 
we stopped both azathioprine and danazol. Subsequently, 
her platelet count was maintained above 100×10
9/L. 
Hemoglobin levels, platelet counts, doses of prednisolone, 
and the timing of medications are illustrated in Fig. 1. 
Currently, she is not taking any medication for ITP or AIHA 
and appears to be in complete remission, except for a slightly 
decreased platelet count (＞110×10
9/L) for about 10 months.
Interestingly, the intermittent peaking of TSH in this pa-
tient was greatly reduced after the use of high-dose pre-
dnisolone and rituximab in combination with a low dose 
of L-thyroxine (0.1 mg). Before the initiation of rituximab, 
her TSH level fluctuated between 0.17 mIU/L and 19.7 Korean J Hematol 2011;46:279-82.
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Fig. 2. Relationship between TSH level and doses of L-thyroxine and rituximab. The unit of L-thyroxin and TSH is ×10
򰠏2 mg and ×10
򰠏2 mIU/L, 
respectively, in this figure. After rituximab treatment, there is no increase in TSH level and the required dose of L-thyroxin is decreased.
mIU/L, even though she was taking a higher dose of L-thyro-
xine (0.15 mg). The doses of L-thyroxine, prednisolone, and 
rituximab, and the TSH levels are presented in Fig. 2. We 
could not follow up the autoantibody level after rituximab 
therapy, because the patient was transferred to another 
hospital. Her last serologic test at our institution showed 
reduction in the titer of anti-nuclear antibody test (1:80×, 
cytoplasmic pattern).
DISCUSSION
Evans syndrome is a rare hematological abnormality char-
acterized by Coombs-positive AIHA and ITP without any 
known underlying cause. This condition may be idiopathic 
or associated with other diseases. First-line therapy is im-
munosuppression, while second-line therapy includes dana-
zol and splenectomy [2, 3]. Various immunosuppressive 
therapies, including Vinca alkaloids, androgens, cortico-
steroids, intravenous immunoglobulin, and splenectomy, 
have been used to treat Evans syndrome. However, both 
medical and surgical treatments have been rather un-
successful in treating refractory cases of Evans syndrome 
[6]. Response rates to conventional agents are variable, and 
some patients require lifelong immunosuppression to keep 
the disease in remission. Rituximab is a chimeric hu-
man/mouse monoclonal antibody that targets CD20 on B 
lymphocytes [7] and is increasingly used for a variety of 
autoimmune disorders, including Evans syndrome [2, 3, 8]. 
Rituximab has also been used to treat disorders associated 
with autoantibody production [9]. 
Previously, many researchers have reported the successful 
use of rituximab for the treatment of patients with cortico-
steroids-refractory Evans syndrome [3, 7, 10, 11]. There have 
been several reports of the co-existence of Evans syndrome 
and thyroid endocrine dysfunction [1, 4, 5]. Recently, there 
have been reports of the use of rituximab for the treatment 
of autoimmune thyroid diseases [12-14]. Rituximab induces 
B cell depletion and decreases the production of thyroid 
autoantibodies. B cell depletion resulted in diminished B 
cell and T cell infiltration in the thyroid, thereby inhibiting 
the development of spontaneous autoimmune thyroiditis. 
This might serve as a potential mechanism of rituximab 
in Hashimoto’s thyroiditis.
Although we could not determine the thyroid autoanti-
body level after rituximab therapy, thyroid functions were 
normalized gradually despite taking a small dosage of 
L-thyroxine. Our results suggest that rituximab therapy may 
be beneficial for patients with Hashimoto’s thyroiditis. To 
our knowledge, our report is the first to describe the stabiliza-
tion of both autoimmune thyroiditis and Evans syndrome 
by the administration of rituximab. Although the causes 
of these diseases remain uncertain, this case suggests a com-
mon immunological mechanism may play an important role 
in the pathogenesis of these diseases and supports the use 
of rituximab in patients with these 3 disorders (Hashimoto’s 
thyroiditis, AIHA, and ITP). 
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